Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of sintilimab + TP chemotherapy + nimotuzumab with IMRT in locally advanced nasopharyngeal carcinoma
ChiCTR2200058765Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Feb 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab, nimotuzumab, paclitaxel and cisplatin in nasopharyngeal carcinoma (NPC), sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Objective response rate and Adverse effects. Started Feb 2021; status: recruiting.
02
Drugs
sintilimabnimotuzumabpaclitaxelcisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2200058765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058765.